Maxime Grimont
Overview
Explore the profile of Maxime Grimont including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
50
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wirbel C, Durand S, Boivin F, Plaschka M, Benboubker V, Grimont M, et al.
Cancer Immunol Immunother
. 2025 Mar;
74(4):141.
PMID: 40056177
Tumor cells can evade antitumor immune response by expressing the PD-L1 ligand, leading to the inhibition of PD-1-expressing T lymphocytes. The mechanisms that regulate PD-L1 expression in cancer cells are...
2.
Gobbini E, Hubert M, Doffin A, Eberhardt A, Hermet L, Li D, et al.
Cancer Immunol Res
. 2025 Jan;
PMID: 39774795
Dendritic cells (DCs) are promising targets for cancer immunotherapies because of their central role in the initiation and control of immune responses. The rare cDC1 population is of particular interest...
3.
Stephan P, Perrot J, Voisin A, Barbery M, Andrieu T, Grimont M, et al.
Haematologica
. 2024 May;
110(1):129-141.
PMID: 38813724
Whereas immunotherapies have revolutionized the treatment of different solid and hematologic cancers, their efficacy in nodal peripheral T-cell lymphomas (PTCL) is limited, due to a lack of understanding of the...
4.
Durand S, Tang Y, Pommier R, Benboubker V, Grimont M, Boivin F, et al.
Oncogene
. 2024 Mar;
43(20):1489-1505.
PMID: 38519642
Cell plasticity sustains intra-tumor heterogeneity and treatment resistance in melanoma. Deciphering the transcriptional mechanisms governing reversible phenotypic transitions between proliferative/differentiated and invasive/stem-like states is required. Expression of the ZEB1 transcription...
5.
Runel G, Lopez-Ramirez N, Barbollat-Boutrand L, Cario M, Durand S, Grimont M, et al.
Cancers (Basel)
. 2024 Feb;
16(4).
PMID: 38398085
The intrinsic biomechanical properties of cancer cells remain poorly understood. To decipher whether cell stiffness modulation could increase melanoma cells' invasive capacity, we performed both in vitro and in vivo...
6.
Noujarede J, Carrie L, Garcia V, Grimont M, Eberhardt A, Mucher E, et al.
Cell Rep
. 2023 Dec;
42(12):113586.
PMID: 38113139
Melanoma is the deadliest form of skin cancer due to its propensity to metastasize. It arises from melanocytes, which are attached to keratinocytes within the basal epidermis. Here, we hypothesize...
7.
Jarrosson L, Dalle S, Costechareyre C, Tang Y, Grimont M, Plaschka M, et al.
EMBO Mol Med
. 2023 Jan;
15(3):e16629.
PMID: 36692026
Metastatic melanoma patients carrying a BRAF mutation can be treated with a combination of BRAF and MEK inhibitors (BRAFi/MEKi), but innate and acquired resistance invariably occurs. Predicting patient response to...
8.
Plaschka M, Benboubker V, Grimont M, Berthet J, Tonon L, Lopez J, et al.
J Immunother Cancer
. 2022 Mar;
10(3).
PMID: 35288462
Background: The efficacy of immunotherapies in metastatic melanoma depends on a robust T cell infiltration. Oncogenic alterations of tumor cells have been associated to T cell exclusion. Identifying novel cancer...
9.
Berthier-Vergnes O, Barbollat-Boutrand L, Pommier R, De la Fouchardiere A, Combemale P, Grimont M, et al.
Mol Cancer
. 2021 Oct;
20(1):127.
PMID: 34600553
No abstract available.